Drug recall · April 11, 2018
Fabior (tazarotene) Foam recall
Why: Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.
- Lots / codes
Lot: MBEB, Exp. 01/31/2019
- Quantity
- 3312 cans
- Company
- Mayne Pharma Inc, Greenville, NC
- Distribution
- Nationwide in the USA
- Initiated
- March 21, 2018 · Voluntary: Firm initiated
- Classified
- March 30, 2018
- Reported
- April 11, 2018
- Ended
- June 11, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Fabior
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.